Our 10 Top Turnaround Situations Under $5.00.
Can These Stocks Double in Value, and Still be 70% off Their Recent High?
Read More...
Biotech Stock Review: Mitesco (MITI) $0.03, Report Update
Mitesco to Launch Telehealth Enabled Primary Care Clinic Business with Q4 Rollout Addressing Healthcare Backlog Accentuated by the Second Wave Concerns.
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
True Nature|Mitesco (TNTY). Coverage Report Issued.
Record Volume and Gradually Rising Price Portends to Higher Prices in 2020 as True Nature Executes on Recently Announced Incubator Strategy.
Smart For Life to Present at The Noble Capital Markets Eighteenth Annual Investor Conference.
MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leading...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at...
SILO Pharma (SILO) Gains 53%
For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun.
Silo Pharma Gains 53%...
Report: Think Equity Updates Society Pass (SOPA). $6.00 Price Target.
Think Equity: Society Pass (Nasdaq: SOPA) – Path to Profitability
NEW YORK, NY, March 14, 2023 (GLOBE NEWSWIRE) --...